VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

KalVista Pharmaceuticals, Inc. (KALV) Total Return Calculator with Dividends Reinvested

KalVista Pharmaceuticals, Inc.

Popular:

The total return for KalVista Pharmaceuticals, Inc. (KALV) stock is +113.93% over the past 12 months. So far it's up 72.83% this year. The 5-year total return is +7.83%, meaning $10,000 invested in KALV stock 5 years ago would be worth $10,783 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in KALV 1 year ago, it would be worth $21,812 today — you'd have gained $11,812.

With Dividends Reinvested$21,812+118.12%

Price Only (No DRIP)$21,812+118.12%

Period2025-05-07 → 2026-05-06

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in KALV

1Y$21,393+$11,393 (+113.9%)113.9% CAGR

3Y$28,008+$18,008 (+180.1%)41.0% CAGR

5Y$10,783+$783 (+7.8%)1.5% CAGR

10Y$25,619+$15,619 (+156.2%)9.9% CAGR

15Y$3,433-$6,567 (-65.7%)-6.9% CAGR

20Y$3,433-$6,567 (-65.7%)-5.2% CAGR

30Y$3,433-$6,567 (-65.7%)-3.5% CAGR

KalVista Pharmaceuticals, Inc. did not pay dividends during this period. Total return = price return.

Loading KALV total return...

As of 2026-05-07

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+72.83%	—	+72.83%	—	$17,283
1Y	+113.93%	113.93%	+113.93%	—	$21,393
3Y	+180.08%	40.96%	+180.08%	—	$28,008
5Y	+7.83%	1.52%	+7.83%	—	$10,783
10Y	+156.19%	9.86%	+156.19%	—	$25,619
15Y	-65.67%	-6.88%	-65.67%	—	$3,433
20Y	-65.67%	-5.21%	-65.67%	—	$3,433
30Y	-65.67%	-3.50%	-65.67%	—	$3,433

Risk & Highlights

Best Year+93.44%2018

Worst Year-84.83%2016

Max Drawdown-32.79%2025-07-17 → 2025-11-04 · Recovered 2025-12-04

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+5.30%	+5.30%	—	+0.41%	+4.9pp
2025	+82.28%	+82.28%	—	+16.64%	+65.6pp
2024	-30.29%	-30.29%	—	+24.00%	-54.3pp
2023	+84.77%	+84.77%	—	+24.81%	+60.0pp
2022	-51.40%	-51.40%	—	-19.95%	-31.5pp

KALV outperformed the S&P 500 by 82.61pp over the past year (+113.93% vs +31.32%).

Loading summary...

KALV Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
KALVKalVista Pharmaceuticals, Inc.	$1.4B	+32.3%	+72.8%	+113.9%	—	+180.1%	+7.8%	+156.2%
BDTXBlack Diamond Therapeutics, Inc.	$161M	+12.8%	+13.3%	+91.8%	—	+46.9%	-89.0%	-92.9%
PRAXPraxis Precision Medicines, Inc.	$7.6B	+9.0%	+18.0%	+860.9%	—	+2005.6%	-18.4%	-19.0%
KALAKALA BIO, Inc.	$855,530	-33.4%	-81.5%	-96.7%	—	-99.3%	-100.0%	-100.0%
XOMAXOMA Royalty Corp.	$493M	+23.3%	+48.6%	+80.6%	—	+127.8%	+33.1%	+188.9%
AGENAgenus Inc.	$137M	+3.2%	+20.4%	+31.0%	—	-87.8%	-93.1%	-93.5%
ADMAADMA Biologics, Inc.	$2.5B	+8.6%	-43.6%	-56.4%	—	+188.0%	+514.6%	+64.7%
HALOHalozyme Therapeutics, Inc.	$7.8B	+5.2%	-5.6%	+11.7%	—	+119.1%	+39.1%	+598.4%
ARDXArdelyx, Inc.	$1.7B	+18.9%	+15.4%	+79.7%	—	+69.5%	+327.7%	+290.1%
PTCTPTC Therapeutics, Inc.	$5.5B	-3.3%	-13.2%	+84.1%	—	+19.9%	+65.2%	+839.5%
RAREUltragenyx Pharmaceutical Inc.	$2.5B	+13.4%	+9.9%	-26.0%	—	-44.9%	-77.6%	-58.9%

Compare:KALV vs BDTX KALV vs PRAX KALV vs KALA KALV vs BDTX vs PRAX

About KALV Dividend Returns

KalVista Pharmaceuticals, Inc. (KALV) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of KALV over the past year?

KalVista Pharmaceuticals, Inc. (KALV) delivered a return of 113.93% over the past year. Since KALV does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in KALV be worth today?

A $10,000 investment in KalVista Pharmaceuticals, Inc. one year ago would be worth $21,393 today, representing a gain of $11,393.

Q3Does KALV pay dividends?

KalVista Pharmaceuticals, Inc. (KALV) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For KALV, the total return equals the price-only return.

Q4Did KALV beat the S&P 500?

Yes, KalVista Pharmaceuticals, Inc. (KALV) outperformed the S&P 500 by 82.61 percentage points over the past year. KALV delivered a total return of 113.93%, compared to the S&P 500's 31.32%. This 82.61pp alpha means investors in KALV earned more than a passive S&P 500 index fund.

Q5What is KALV's worst drawdown?

KalVista Pharmaceuticals, Inc. (KALV) experienced a maximum drawdown of -32.79% over the past year, declining from its peak on 2025-07-17 to its trough on 2025-11-04. The stock recovered to its prior peak by 2025-12-04. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is KALV's long-term total return over 10, 20, or 30 years?

Here are KalVista Pharmaceuticals, Inc. (KALV)'s long-term returns with dividends reinvested. Over 10 years, the total return is 156.2% (9.9% CAGR) — $10,000 would have grown to $25,619. Over 20 years: -65.7% total return (-5.2% CAGR) — $10,000 → $3,433. Over 30 years: -65.7% total return (-3.5% CAGR) — $10,000 → $3,433. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was KALV's best and worst year?

KalVista Pharmaceuticals, Inc.'s best calendar year was 2018 with a total return of 93.4%. Its worst year was 2016 with a total return of -84.8%. This range shows the volatility investors should expect — the difference between the best and worst year is 178.3 percentage points.